HOME >> BIOLOGY >> NEWS
Chromosomal microarray analysis proves accurate

Two years and more than 2,000 samples after researchers at Baylor College of Medicine started to use a new gene-chip technology called chromosomal microarray analysis to look for potential genetic abnormalities in children, they find that it is remarkably sensitive in detecting abnormalities in individual chromosomes, according to a report that appears online today in the journal Public Library of Science ONE.

"Chromosomal microarray analysis is far better at picking up these abnormalities than other common methods," said Dr. Arthur Beaudet, chair of the department of molecular and human genetics at BCM and an author of the paper. "It allows us to identify the source of abnormalities in many cases."

He said the technique does not help with identifying the problem in all children, but there is a five to 12 percent chance that it will identify an abnormality in children with various disabilities where the previous chromosomal testing did not. This study involved two versions of the test, and the newer version was more successful in identifying chromosomal abnormalities.

The targeted microarray analysis used here is essentially a gene chip method of assessing the makeup of chromosomes in a particular part of the human genome (genetic blueprint).

In areas of the genome, there are portions of the genetic material that show imbalances because they are duplicated or deleted abnormally with gains and losses of genetic information.

"If these changes are big enough, they can cause significant disabilities," said Beaudet.

The technique used is also much more efficient, making it possible to do the equivalent of a couple of thousand of more common testing methods in one test.

"If you tried to do these individually, it would be cost prohibitive," said Beaudet. Currently, chromosomal microarray analysis costs from $950 to $1,500.

In the current study, Beaudet and his colleagues analyzed the result
'"/>

Contact: Ross Tomlin
htomlin@bcm.edu
713-798-4710
Baylor College of Medicine
28-Mar-2007


Page: 1 2

Related biology news :

1. Chromosomal tests can determine brain tumor therapy, outcomes, Jefferson oncologists find
2. Chromosomal abnormalities in sperm higher after vasectomy reversal
3. NIH neuroscience microarray consortium launches high-throughput genotyping services
4. Study identifies common flaws in oncology microarray studies
5. Bayer HealthCare licenses Genomatix for microarray analysis
6. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool
7. Different microarray systems more alike than previously thought
8. Standardized microarrays may bring us one step closer
9. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
10. Genetic analysis finds greater threat in frog-killing fungus
11. Genomic analysis uncovers new targets for HIV vaccine

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Chromosomal microarray analysis proves accurate

(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
Cached News: